ClinicaliQ Trial Snapshot
- Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors — Recruiting • Phase I • Oncology • NCT05985655.
- What is being tested: GTAEXS617 (REC-617), a novel therapeutic agent, is being evaluated for safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced solid tumors through a clinical trial design.
- Patient eligibility overview: The study includes participants with advanced solid tumors; specific eligibility criteria (such as performance status, prior treatment history, and organ function) would determine which patients can be enrolled.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
Eligibility Snapshot
- Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Life expectancy > 3 months. * One of the following histologically or cytologically confirmed advanced solid tumors: head and neck squamous cell carcinoma (HNSCC), pancreatic adenocarcinoma, non-small cell lung cancer (NSCLC), breast carcinoma (hormone receptor-positive [HR+] and Human Epidermal Growth Receptor 2 negative [HER2-] that has progressed to a prior treatment with Cyclin-Dependent Kinase 4 (CDK4)/ Cyclin-Dependent Kinase 6 [CDK6] inhibitor), or platinum-resistant high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers (HGSOC), or triple negative breast cancer (TNBC). * Must have disease that is advanced (ie, surgery or radiotherapy are not considered to be potentially curative), recurrent, or metastatic following SoC treatments. * Adequate hematological, liver, and renal function. * Must have tumor lesion(s) or metastases amenable to biopsy, excluding bone metastases. Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.